Short-term Effectiveness and Safety of Ustekinumab and Vedolizumab in Elderly and Non-elderly Patients with Crohn's Disease: a Comparative Study

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2024 Nov 21

PMID 39569055

Authors

Lior Dar

Uria Shani

Arad Dotan

Offir Ukashi

Shomron Ben-Horin

Uri Kopylov

Asaf Levartovsky

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory bowel disease (IBD) presents unique challenges in elderly patients due to comorbidities and treatment-related risks.

Objectives: This study evaluates ustekinumab (UST) and vedolizumab (VDZ) efficacy and safety in elderly Crohn's disease (CD) patients.

Design: A retrospective cohort study at a tertiary medical center.

Methods: CD patients aged ⩾60 years (elderly) treated with UST, compared to non-elderly (<60 years) patients treated with UST and elderly patients treated with VDZ. Clinical response was evaluated using the Harvey-Bradshaw index (HBI) and clinical biomarkers, alongside monitoring steroid use, hospitalization rates, treatment persistence, and surgical interventions.

Results: The study included 166 CD patients: 32 elderly and 65 non-elderly patients treated with UST, and 69 elderly patients treated with VDZ. The mean duration of follow-up was 10.8 ± 2.8 months in the non-elderly group, 9.97 ± 3.28 months in the elderly UST group, and 10.0 ± 3.29 months in the VDZ group. Elderly UST patients were more likely to receive corticosteroids at initiation than non-elderly UST patients (44% vs 14%, = 0.001). At 12 months, clinical response rates did not significantly differ between elderly and non-elderly UST groups, respectively (48% vs 40%, = 0.5). However, elderly UST patients exhibited higher hospitalization rates over time compared to non-elderly UST patients (6-month: 19% vs 6.2%, = 0.077; 12-month: 19% vs 4.6%, = 0.055; log-rank = 0.004). No significant differences were observed in clinical response and remission rates between elderly UST and elderly VDZ patients at 6 and 12 months. At 6 months, a higher hospitalization rate was observed in the UST group (19% vs 4.3% = 0.027), but this difference did not persist over time.

Conclusion: UST and VDZ are effective and safe treatments for elderly CD patients, despite higher hospitalization rates compared to non-elderly patients, likely due to age-related complications.

References

Hahn G, Golovics P, Wetwittayakhlang P, Santa Maria D, Britto U, Wild G . Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. J Clin Med. 2022; 11(15). PMC: 9369299. DOI: 10.3390/jcm11154422. View

Khan N, Vallarino C, Lissoos T, Darr U, Luo M . Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients. Drugs Aging. 2017; 34(11):859-868. PMC: 5705754. DOI: 10.1007/s40266-017-0498-y. View

Garg R, Aggarwal M, Mohammed A, Achkar J, Lashner B, Philpott J . Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease. Indian J Gastroenterol. 2023; 42(5):718-723. PMC: 10993992. DOI: 10.1007/s12664-023-01391-3. View

Feagan B, Sandborn W, Gasink C, Jacobstein D, Lang Y, Friedman J . Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016; 375(20):1946-1960. DOI: 10.1056/NEJMoa1602773. View

Gebeyehu G, Fiske J, Liu E, Limdi J, Broglio G, Selinger C . Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients. Dig Dis Sci. 2022; 68(5):1983-1994. PMC: 9702964. DOI: 10.1007/s10620-022-07770-8. View

Fiske J, Liu E, Limdi J, Conley T, Townsend T, Davies M . Safety and effectiveness of ustekinumab in elderly Crohn's disease patients. Eur J Gastroenterol Hepatol. 2022; 34(11):1132-1139. DOI: 10.1097/MEG.0000000000002436. View

Casas-Deza D, Lamuela-Calvo L, Gomollon F, Arbones-Mainar J, Caballol B, Gisbert J . Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry. J Crohns Colitis. 2022; 17(1):83-91. DOI: 10.1093/ecco-jcc/jjac108. View

Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G . Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharmacol Ther. 2022; 56(1):95-109. PMC: 9324100. DOI: 10.1111/apt.16923. View

Iborra M, Beltran B, Fernandez-Clotet A, Gutierrez A, Antolin B, Huguet J . Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2019; 50(3):278-288. DOI: 10.1111/apt.15371. View

10.

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert J, Raine T . ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2019; 14(1):4-22. DOI: 10.1093/ecco-jcc/jjz180. View

11.

Eberl A, Hallinen T, Af Bjorkesten C, Heikkinen M, Hirsi E, Kellokumpu M . Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019; 54(6):718-725. DOI: 10.1080/00365521.2019.1624817. View

12.

Holvoet T, Truyens M, De Galan C, Peeters H, Mesonero Gismero F, Elorza A . Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. J Clin Med. 2024; 13(2). PMC: 10816258. DOI: 10.3390/jcm13020365. View

13.

. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019; 5(1):17-30. PMC: 7026709. DOI: 10.1016/S2468-1253(19)30333-4. View

14.

Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos G, Bonovas S . Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 51(9):820-830. DOI: 10.1111/apt.15692. View

15.

Solitano V, Facciorusso A, Jess T, Ma C, Hassan C, Repici A . Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022; 21(4):907-921.e2. DOI: 10.1016/j.cgh.2022.07.032. View

16.

Borren N, Ananthakrishnan A . Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2019; 17(9):1736-1743.e4. PMC: 6609492. DOI: 10.1016/j.cgh.2018.12.032. View

17.

Bokemeyer B, Picker N, Kromer D, Rosin L, Patel H . Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. Int J Colorectal Dis. 2023; 38(1):116. PMC: 10164668. DOI: 10.1007/s00384-023-04397-7. View

18.

Colombel J, Sands B, Rutgeerts P, Sandborn W, Danese S, DHaens G . The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2016; 66(5):839-851. PMC: 5531223. DOI: 10.1136/gutjnl-2015-311079. View

19.

Biemans V, van der Meulen-de Jong A, van der Woude C, Lowenberg M, Dijkstra G, Oldenburg B . Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2019; 14(1):33-45. PMC: 7142409. DOI: 10.1093/ecco-jcc/jjz119. View

20.

Clement B, De Felice K, Afzali A . Indications and safety of newer IBD treatments in the older patient. Curr Gastroenterol Rep. 2023; 25(7):160-168. PMC: 10209934. DOI: 10.1007/s11894-023-00874-9. View